ClinicalTrials.gg
CompletedNCT02968173Synagis RussiaUpdated Mar 13, 2018Results posted

A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus

A Phase 3 interventional study of Palivizumab in Respiratory Syncytial Virus (RSV), sponsored by AbbVie. Completed. Open to participants aged Up to 24 Months. Per ClinicalTrials.gov, last updated 2018-03-13.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
Up to 24 Months
Sex
All
01

Study summary

This is a Phase 3b, prospective, multicenter, open-label, non-controlled study to assess the safety and effectiveness of immunoprophylaxis with the intramuscular (IM) administration of the liquid formulation of palivizumab for the prevention of RSV hospitalizations in infants at high risk (infants born at less than or equal to 35 weeks gestational age and less than or equal to 6 months of age at enrollment; or infants less than or equal to 24 months of age with a diagnosis of chronic lung disease [CLD] of prematurity requiring on-going medical treatment within the previous 6 months or infants less than or equal to 24 months of age with hemodynamically significant congenital heart disease [CHD]).

Read the detailed description

Participants will receive palivizumab solution for injection at 15 mg/kg by IM injection every 30 days for a minimum of 3 and a maximum of 5 injections given during anticipated periods of RSV risk in the community; the number of doses will depend on the time of enrollment during the RSV season.

02

Conditions studied

  • Respiratory Syncytial Virus (RSV)

Keywords

  • Bronchopulmonary dysplasia (BPD)
  • RSV hospitalization
  • Palivizumab
  • Immunoprophylaxis
  • Chronic lung disease (CLD) of prematurity
03

In context

Bronchopulmonary Dysplasia

362 studies on the registry are indexed under Bronchopulmonary Dysplasia; 84 are open to participants now.

This study's enrollment of 50 is below the median of 66 across 244 interventional studies indexed under Bronchopulmonary Dysplasia.

Browse Bronchopulmonary Dysplasia studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Infants at high risk of severe RSV infection defined as fulfilling at least one of the following:

  • Infants born ≤ 35 weeks gestational age AND are ≤ 6 months of age at enrollment
  • Infants ≤ 24 months of age at enrollment AND with a diagnosis of bronchopulmonary dysplasia (BPD) (defined as oxygen requirement at a corrected gestational age of 36 weeks) requiring intervention/management (i.e., oxygen, diuretics, bronchodilators, , etc.) anytime within 6 months prior to enrollment
  • Infants ≤ 24 months of age at enrollment with hemodynamically significant CHD, either cyanotic or acyanotic, unoperated or partially corrected. Children with acyanotic cardiac lesions must have pulmonary hypertension (≥ 40 mmHg measured pressure in the pulmonary artery [ultrasound acceptable]) or the need for daily medication to manage hemodynamically significant CHD

Exclusion criteria

Exclusion Criteria (main exclusion criteria):

  • Hospitalization at the time of enrollment (unless discharge is anticipated within 14 days)
  • Mechanical ventilation (including continuous positive airway pressure, CPAP) at the time of enrollment
  • less than 6 months
  • Unstable cardiac or respiratory status, including cardiac defects so severe that survival is not expected or for which cardiac transplantation is planned or anticipated
  • Active respiratory illness, or other acute infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Children at High Risk of severe RSV Infection

    A single IM injection every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a participant was enrolled.

    Drug: Palivizumab

Interventions

  • Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed to an epitope in the A antigenic site of the F (fusion) protein of RSV.

    Also known as: Synagis

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With RSV Hospitalization

    An RSV hospitalization is defined as either 1) a respiratory/cardiac hospitalization with a positive RSV test, 2) new onset of respiratory/cardiac symptoms in an already hospitalized child, with an objective measure of worsening respiratory/cardiac status and a positive RSV test, or 3) deaths, which can be demonstrated as caused by RSV (by autopsy or clinical history and virologic evidence).

    Time frame: Approximately 6 months

Secondary outcomes

  1. Total Number of RSV-Hospitalization Days

    Time frame: Approximately 6 months

  2. Percentage of Participants Who Received Supplemental Oxygen While Hospitalized

    Increased supplemental oxygen is defined as a new requirement or an increase in supplemental oxygen from prior to the onset of cardiac/respiratory symptoms.

    Time frame: Approximately 6 months

  3. Total RSV-hospitalization Days With Increased Supplemental Oxygen Requirement

    Increased supplemental oxygen is defined as a new requirement or an increase in supplemental oxygen from prior to the onset of cardiac/respiratory symptoms.

    Time frame: Approximately 6 months

  4. Number of Intensive Care Unit (ICU) Admissions During RSV-hospitalization

    Time frame: Approximately 6 months

  5. Total Days of RSV-ICU Stay

    Time frame: Approximately 6 months

  6. Percentage of Participants Who Received Mechanical Ventilation

    Time frame: Approximately 6 months

  7. Total Days of Mechanical Ventilation During RSV-hospitalization

    Time frame: Approximately 6 months

07

Results

Posted Mar 13, 2018

Participant flow

Participant flow — Overall Study
MilestoneChildren at High Risk of Severe RSV Infection
Started50
Completed49
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants With RSV Hospitalization

An RSV hospitalization is defined as either 1) a respiratory/cardiac hospitalization with a positive RSV test, 2) new onset of respiratory/cardiac symptoms in an already hospitalized child, with an objective measure of worsening respiratory/cardiac status and a positive RSV test, or 3) deaths, which can be demonstrated as caused by RSV (by autopsy or clinical history and virologic evidence).

Time frame:
Approximately 6 months
Reported as:
Number · percentage of participants
Percentage of Participants With RSV Hospitalization
percentage of participantsChildren at High Risk of Severe RSV Infection
Percentage of Participants With RSV Hospitalization0.0 (0.0 to 7.1)
SecondaryTotal Number of RSV-Hospitalization Days
Time frame:
Approximately 6 months

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Received Supplemental Oxygen While Hospitalized

Increased supplemental oxygen is defined as a new requirement or an increase in supplemental oxygen from prior to the onset of cardiac/respiratory symptoms.

Time frame:
Approximately 6 months

No measurements were reported for this outcome.

SecondaryTotal RSV-hospitalization Days With Increased Supplemental Oxygen Requirement

Increased supplemental oxygen is defined as a new requirement or an increase in supplemental oxygen from prior to the onset of cardiac/respiratory symptoms.

Time frame:
Approximately 6 months

No measurements were reported for this outcome.

SecondaryNumber of Intensive Care Unit (ICU) Admissions During RSV-hospitalization
Time frame:
Approximately 6 months

No measurements were reported for this outcome.

SecondaryTotal Days of RSV-ICU Stay
Time frame:
Approximately 6 months

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Received Mechanical Ventilation
Time frame:
Approximately 6 months

No measurements were reported for this outcome.

SecondaryTotal Days of Mechanical Ventilation During RSV-hospitalization
Time frame:
Approximately 6 months

No measurements were reported for this outcome.

Adverse events

Collected over From first dose of study treatment through the last prophylaxis visit (up to Day 120 [±5 days]) + 30 days (+5 days) and 100 days (+5 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PALIVIZUMAB TEAE Within 30 Days0/50 (0%)6/50 (12%)0/50 (0%)
PALIVIZUMAB TEAE Within 100 Days0/50 (0%)6/50 (12%)0/50 (0%)
Most frequent serious events
Most frequent serious events
EventPALIVIZUMAB TEAE Within 30 DaysPALIVIZUMAB TEAE Within 100 Days
Tachycardia paroxysmalCardiac disorders1/501/50
BronchitisInfections and infestations1/501/50
Bronchitis viralInfections and infestations1/501/50
NasopharyngitisInfections and infestations1/501/50
PneumoniaInfections and infestations1/501/50
Respiratory tract infection viralInfections and infestations1/501/50
HaemangiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/501/50

Baseline characteristics

Age, Continuous
Age, Continuous(months)Children at High Risk of Severe RSV Infection
Mean6.22 ± 4.428
Sex: Female, Male
Sex: Female, Male(Participants)Children at High Risk of Severe RSV Infection
Female24
Male26
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Children at High Risk of Severe RSV Infection
Hispanic or Latino0
Not Hispanic or Latino50
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Children at High Risk of Severe RSV Infection
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White50
More than one race0
Unknown or Not Reported0
08

Study locations

No study locations are listed for this record.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Jul 2017, 8 months.

Results were first posted in Mar 2018, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2016
First posted
Nov 18, 2016
StartActual
Nov 9, 2016
Primary completionActual
Jul 13, 2017
CompletionActual
Jul 13, 2017
Results first posted
Mar 13, 2018
Last update
Mar 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02968173
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 18, 2016
Start date
Nov 9, 2016
Primary completion
Jul 13, 2017
Completion
Jul 13, 2017
Results posted
Mar 13, 2018
Last update
Mar 13, 2018

Study contacts

Joaquin Valdes
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palivizumab

Start the discussion